A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer

In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Chenchen, Wei, Yufan, Li, Jianjun, Huang, Zhi, Wang, Qiong, Lin, Yingxue, Lv, Xingping, Chen, Yanan, Fan, Yan, Sun, Peiqing, Xiang, Rong, Chang, Antao, Yang, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911181/
https://www.ncbi.nlm.nih.gov/pubmed/35270034
http://dx.doi.org/10.3390/ijms23052892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911181/
https://www.ncbi.nlm.nih.gov/pubmed/35270034
http://dx.doi.org/10.3390/ijms23052892

Ejemplares similares